Article Text

PDF
Treatment with antidepressants and lithium is associated with increased risk of treatment with antiparkinson drugs: a pharmacoepidemiological study
  1. M Brandt-Christensen1,
  2. K Kvist2,
  3. F M Nilsson3,
  4. P K Andersen2,
  5. L V Kessing1
  1. 1Department of Psychiatry, University Hospital of Copenhagen, Rigshospitalet, Denmark
  2. 2Department of Biostatistics, University of Copenhagen, Denmark
  3. 3Department of Psychiatry, University Hospital of Copenhagen, Amager, Denmark
  1. Correspondence to:
 Dr M Brandt-Christensen
 Department of Psychiatry, University of Copenhagen, Rigshospitalet, Blegdamsvej 9, DK 2100 Copenhagen, Denmark; mette.brandt{at}rh.dk

Abstract

Objective: To estimate the risk for persons treated with antidepressants or lithium of subsequent treatment with antiparkinson drugs (APD).

Methods: The Danish national prescription database supplied data on all persons who received antidepressants, lithium, or antidiabetics (first control group). A second control group was included comprising persons from the general population. Outcome was purchase of APD and the study period was 1995 to 1999.

Results: In total, 1 293 789 persons were included. The rate ratio of treatment with APD after treatment with antidepressants was 2.27 (95% CI 2.14 to 2.42) for men and 1.50 (95% CI 1.43 to 1.58) for women. Figures for lithium were almost identical.

Conclusion: Persons treated with antidepressants or lithium are at increased risk of subsequently treatment with APD, showing an association between anxiety/affective disorder and Parkinson’s disease.

  • APD, antiparkinson drugs
  • PD, Parkinson’s disease
  • ATC, anatomical therapeutic classification
  • RR, rate ratio
  • affective disorder
  • Parkinson’s disease
  • pharmacoepidemiology

Statistics from Altmetric.com

Footnotes

  • Funding: this study was supported by The Lundbeck Foundation.

  • Competing interests: None declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.